Liquid biopsy is revolutionizing tumor diagnostics by offering a non-invasive approach that analyzes blood samples to detect cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA). While cfDNA encompasses fragments from both healthy and tumor cells, ctDNA originates exclusively from tumors, providing invaluable genetic insights. Our liquid biopsy method eliminates the need for invasive tissue biopsies and delivers detailed genotyping, enabling the identification of specific mutations. Moreover, our liquid biopsy is highly effective for monitoring minimal residual disease (MRD), tracking disease progression, and assessing treatment response by measuring ctDNA levels. This precise and convenient testing enhances patient care by offering valuable information for personalized treatment strategies.
LymphoVista and LymphoVista HL are specifically designed to monitor the progression of lymphoma in general and Hodgkin lymphoma, respectively. By tracking multiple mutations, LymphoVista and LymphoVista HL can detect minimal residual disease (MRD) down to a sensitivity of 1 in 1.000.000 molecules, significantly surpassing the capabilities of standard PET-CT technology. LymphoVista HL enables you to track disease progression and therapy efficacy with greater precision. This increased sensitivity allows for earlier detection of potential relapses, providing valuable information for informed treatment decisions.
Our medical report provides comprehensive and scientifically rigorous information on genetic variants and minimal residual disease (MRD) detected through liquid biopsy analysis.
Key features include: